About Caladrius

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases.

News

August 8, 2019
Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update

August 7, 2019
Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

August 1, 2019
Caladrius Biosciences to Host 2019 Second Quarter Financial Results Conference Call on Thursday, August 8, 2019 at 4:30 p.m. Eastern Time

Events

August 8, 2019
Caladrius Biosciences 2nd Quarter 2019 Financial Results and Business Update Conference Call

May 9, 2019
Caladrius Biosciences 1st Quarter 2019 Financial Results and Business Update Conference Call

March 21, 2019
ARM’s Cell & Gene Therapy Investor Day

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology